Levak, Nicholas
Lehtisalo, Jenni
Thunborg, Charlotta
Westman, Eric
Andersen, Pia
Andrieu, Sandrine
Broersen, Laus M.
Coley, Nicola
Hartmann, Tobias
Irving, Gerd Faxén
Mangialasche, Francesca
Ngandu, Tiia
Pantel, Johannes
Rosenberg, Anna
Sindi, Shireen
Soininen, Hilkka
Solomon, Alina
Wang, Rui
Kivipelto, Miia
Funding for this research was provided by:
Alzheimerfonden
Demensfonden
EU Joint Programme – Neurodegenerative Disease Research
ZonMw (733051041)
Hjärnfonden
Forskningsrådet om Hälsa, Arbetsliv och Välfärd
European Research Council (804371)
Center for Innovative Medicine
Knut och Alice Wallenbergs Stiftelse
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Karolinska Institutet
NordForsk
Karolinska Institute
Article History
Received: 26 March 2024
Accepted: 26 June 2024
First Online: 3 July 2024
Declarations
:
: MIND-AD<sub>mini</sub> was conducted in compliance with Good Clinical Practice and in accordance with the Declaration of Helsinki, and other applicable regulatory requirements. This study received approval from the French Ethical Committee in Bordeaux (DNR: 2018-A02119-46; the ethics committee at the University Hospital Fashberichs, Goethe University, Frankfurt am Main (DNR: 46/18 0806–2018); the ethics committee in Stockholm (2016/2605–31/1, 2017/1466–32, 2017/2165–32, 2018/598–32); and the Finnish research ethics committee (190/13.02.00/2017). Prior to enrolment in the trial, participants and their study partners provided written informed consent.
: Not applicable.
: LMB is an employee of Danone Nutricia Research.